Models of good practice in drug treatment in Europe. Project group

Similar documents
Substance use and misuse

The available evidence in the field of treatment of opiate: The experience of developing the WHO clinical guidelines

OST saves lives it s official! OST a key to HIV prevention Opioid Substitution Treatment in Germany A Story of Success

Strategies of drug users to avoid infection with hepatitis C

Technical Guidance Note for Global Fund HIV Proposals

Should buprenorphine be covered for maintenance treatment in opioid dependent persons?

HIV in Prison Situation in Frankfurt am Main

Exploring Barriers & Solutions in Facilitating Detox

HA Corporate Scholarship Program:

The science of the mind: investigating mental health Treating addiction

Promoting hepatitis B vaccination

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

The impact of economic recession on drug users and drug treatment

Drug treatment and prevention in Tartu prison. Maret Miljan Department of Prisons Ministry of Justice Estonia

GLOBAL DRUG POLICY AND THE HIV/IDU EPIDEMIC IN EASTERN EUROPE AND CENTRAL ASIA. The critical need to scale up opioid substitution therapy

Strategies to Reduce Harm and HIV/AIDS Infection among Drug Using Populations

KAZAKHSTAN. National Focal Point. Drug Abuse and Drug Dependence Treatment Situation. Territory : 2,717,300 km 2 Capital: Astana BASIC DATA

Prevalence of HIV and risk behaviors among injecting drug users in Tallinn, Estonia in a series of cross-sectional studies

QUARTERLY PROVIDER MEETING MARCH 9, 2017 SUZANNE BORYS, ED.D.

ORGANIZATION OF AMERICAN STATES

Opioid Withdrawal, Opioid Substitution, and HIV Infection

The effectiveness of interventions related to the use of illicit drugs: prevention, harm reduction, treatment and recovery. A review of reviews

HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons

The Comprehensive Package: The simple truth about our response to drug related HIV. Dr. Monica Beg, Signe Rotberga UNODC

WHAT IS HARM REDUCTION?

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

As a result of this training, participants will be able to:

INTER-AMERICAN DRUG ABUSE CONTROL COMMISSION C I C A D

PH52. Audit tool for the implementation of. NICE public health guidance 52 Needle and syringe programmes

Substance Abuse Suboxone Treatment

Prevention and control of Hepatitis B and C among vulnerable groups Estonia: People who use drugs

HARM REDUCTION & TREATMENT. Devin Reaves MSW

As a result of this training, participants will be able to:

Opioid Withdrawal, Opioid Substitution Treatment, and HIV Infection

Methadone Treatment as a Harm Reduction Strategy, Gender Sensitive Programming and Evidence-based Strategies

HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications

Poland nationalupdate

ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)

State Targeted Opioid Response Initiative (STORI) Fee-for-Service (FFS) Open Enrollment

Chad Sabora, BS, MS, JD Missouri Network for Opiate Reform and Recovery. Drug Policy, Harm Reduction, and What s Next

Note: Staff who work in case management programs should attend the AIDS Institute training, "Addressing Prevention in HIV Case Management.

Medical Director. and in prison settings in Romania. Ministry of Justice National Administration of Penitentiaries L IŢ

How Can Injectable Hydromorphone and Pharmaceutical-Grade Heroin be Used to Treat Opioid Use Disorder?

26 28 May 2010, Almaty, Kazkhstan. Nina Kerimi UNODC Regional Project Coordinator 1

Building capacity for a CHC response to Ontario's Opioid Crisis

NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification

BROMLEY JOINT STRATEGIC NEEDS ASSESSMENT Substance misuse is the harmful use of substances (such as drugs and alcohol) for non-medical purposes.

Addiction and Substance misuse pathways

Drug demand reduction and harm reduction: complementary approaches. Gilberto Gerra Chief Global Challenges Section Division for Operations

EMCDDA-update HIV/HCV among people who inject drugs: situation and response

Buprenorphine: An Introduction. Sharon Stancliff, MD Harm Reduction Coalition September 2008

Drug Consumption Rooms: Legal barriers or just an excuse? Kirstie Douse Head of Legal Services Solicitor Advocate

Intervention from the World Health Organization

The Importance of Psychological Treatment and Behavioral Support

Treatment Approaches for Drug Addiction

PERSPECTIVES ON DRUGS Characteristics of frequent and high-risk cannabis users

Guidelines For Services Providing Injecting Equipment

Statement by the Portuguese Deputy Minister for Health. Vienna, 8 March 2010

This document was generated by the Reference Group to the United Nations on HIV and Injecting Drug Use.

Should Methadone and/or Buprenorphine be included in the WHO Model List of Essential Medicines? Reviewing evidence from Iranian experience.

Conor K Farren. St Patricks University Hospital Trinity College Dublin Ireland

JSNA Substance Misuse

What is harm reduction?

Diversion, misuse and trafficking of methadone and buprenorphine: Impact on recovery

Cocaine users: a special population? The evidence for policy and practice. SSA Conference 2005 Luke Mitcheson, South London and Maudsley NHS Trust

National Guidelines. Interim methadone prescribing

NSPs in Estonia: current situation and future challenges

Managing drug misuse in pregnancy and beyond

Injecting trends in Austria including results of a systematic literature review on interventions aiming to influence the route of administration

Hepatitis prevention in the context of HIV prevention point work in Latvia

Historical Perspectives

Methadone Diversion: Why it happens, what the illicit market looks like and the implications

HARM REDUCTION LAUREN PREST ADDICTION PSYCHIATRY FELLOW 2018 UNIVERSITY OF UTAH HEALTH, 2018

The Misuse of Opiate Substitution Therapy: an Obstacle for the Diffusion of Best Practice in Italy Lisbon, 23 September 2015

Scientific Facts on. Psychoactive Drugs. Tobacco, Alcohol, and Illicit Substances

PREVENTION STRATEGIES RELATED TO HIV/AIDS Narra Smith Cox, Ph.D., CHES

European Legal Database on Drugs

HIV AND PEOPLE WHO INJECT DRUGS

Family Health Centers of San Diego Alcohol and Other Drug Services

The role of UNODC in working law enforcement agencies to promote harm reduction. IHRC, Bangkok, 23 April 2009

Part 1: Introduction & Overview

Dr. dr. Diah Setia Utami, SpKJ, MARS Deputy of Rehabilitation Narcotic National Board of Republic of Indonesia

Background. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)

CROATIA. Venija Cerovecki, MD, GP. University of Zagreb School of Medicine Department for Family Medicine

Public drug policies Catalonia

Statistics from the Northern Ireland Drug Misuse Database: 1 April March 2011

Harms and harm reduction workbook. Country X

Opioid Withdrawal, Opioid Substitution, and HIV Infection

Primary Health Networks

COUNTRY TABLE. MONTENEGRO.

Signs of success latest national NESI data?

Management Options for Opioid Dependence:

Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD

Harm Reduction Database Wales: Needle and Syringe provision

Infectious and Communicable Diseases Prevention and Control Program Annual Service Plan A. Community Need and Priorities We are situated rurally with

Trigger. Myths About the Use of Medication in Recovery BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS

Service Specification: Bristol and South Gloucestershire Specialist Substance Misuse Treatment Service January 2016

Jerry Cochran, MSW, PhD University of Utah School of Medicine Department of Internal Medicine Department of Psychiatry

Drug Misuse Research Division

The evolution of the HIV/AIDS outbreak among IDUs in Romania

Transcription:

Models of good practice in drug treatment in Europe ( moretreat 2006329 ) Project group Hamburg, London, Rome, Stockholm, Vienna, Warsaw, Zurich Project duration: 17 months from April 2006 August 2008

Objectives and Tasks To encourage drug treatment strategies which enable to reach substance users on an earlier stage of their addiction career to improve their integration and health Identify, collect and evaluate models of good practice in drug treatment in Europe Formulation of good practice guidelines for key interventions in drug treatment Carry out an inventory of effectiveness of drug treatment Evidence based recommendations for central drug treatment modalities Improve the quality of drug treatment services in the EU-Member States Exchange of good practices in drug treatment was supported Based on consensus process 16.10.2012 2

What has been done European inventory of good practice of drug treatment interventions and their effectiveness based on Scientific reviews of international and European (published in English) evidence Regional search for most relevant studies - realised by the partners resulted in Development of European evidence-based guidelines for good practice with respect to different drug treatment interventions/modalities 16.10.2012 3

Evidence-based guidelines for key interventions Dimensions approach, context, duration, staff, client groups, eligibility, inclusion and exclusion criteria, treatment access to service, referral pathways, integrated care pathways Standards management standards, commissioning standards, responsibilities, performance/outcome monitoring, seamless provision of services and support from one setting to the other (e.g. community prisons/hospitals, psychiatry), care coordination, departure planning, monitoring Assessment process-management, phases of treatment, performance/outcome monitoring 16.10.2012 4

Guidelines for key interventions in drug treatment Enhancing motivation for change Maintenance treatment Detoxification Cross-cutting issues Treatment for clients with co-occurring disorders Interventions in blood-borne diseases Drug treatment Treatment in criminal justice sys. Treatment for stimulant use disorders Pregnancy and parenting Systemic aspects of treatment Brief interventions therapies Psychosocial interventions 16.10.2012 5

Main findings on effectiveness - in brief Motivational Enhancement Therapy Especially good outcomes at early stages of treatment MI seems to increase the effect of another treatment Psychosocial interventions Have an effect on drug dependence - no form of psychosocial treatment works better than another Psychosocial treatment usually improves substitution maintenance treatment outcomes Maintenance treatment Methadone is the best-studied and most effective opioid agonist Treatment outcome is improved with increased dosages and the provision of adequate psychosocial support Detoxification Methadone with equal dose decrease is the standard detoxification Efficacy of buphrenorphine is comparable to methadone 16.10.2012 6

Main findings on effectiveness - in brief Brief interventions (one or more sessions to reduce individual harm) High efficacy for cognitive-behavioural therapy, positive effects of family and social therapies Mostly concentrated on problem use of cannabis and stimulants Treatment in criminal justice system All community services can be offered in prison (medical and drug-free treatment as well as harm reduction) Combination of prison-treatment and continuity of care after release is most effective Treatment for co-occurring disorders Three types of interventions are probably effective: Group counselling, contingency management, long-term residential treatment Treatment for stimulant use Limited evidence available shows that most patients can be effectively treated in intensive outpatient programmes There is no evidence for prescribing antidepressants 16.10.2012 7

Effectiveness of Harm Reduction Needle and syringe exchange services Strong evidence that availability of NSP contributes to the control of HIV among IDUs May be effective in reducing drug use frequency, transition from i.v. to smoking Drug consumption rooms Positive outcome on health status + risk behavior (reduction of drug-related deaths) Improve enrolment and retention in drug treatment Testing and vaccination No clear evidence for effectiveness of testing for blood-borne diseases Vaccination against hepatitis B is strongly effective in preventing hepatitis B infection HBV vaccination seems to have a positive influence on the hepatitis C serostatus Information and education Only few studies: most effective in combination with other prevention strategies On the short-term in may be effective in raising awareness for risks All interventions are less effective in preventing hepatitis C infection 16.10.2012 8

Summary There is a wide range of different drug treatment interventions (concepts, methods, aims) Not all interventions delivered in Europe have shown to be effective Three main types of interventions Pharmacological treatment aim at reduction or cessation of opioid use Maintenance treatment shows better outcome than detoxification Reduction of illicit drug use and crime, decrease of mortality Psychosocial interventions aim at motivation to change drug use and risk behaviour CBT and MI often focused on cocaine/cannabis users or young drug users Coping with risk-situations, reduction of drug use Harm reduction aim at control or reduction of blood-borne diseases NSP programmes, drug consumption rooms, vaccination addressed to IDUs Decrease of sharing of drug use equipment, prevention of overdoses 16.10.2012 9

Conclusions situation in Europe Most available literature exists for medical treatment Detoxification and maintenance treatment with different substances (especially methadone, buphrenorphine and heroin) Despite: Out 148 studies only 56 are from Europe (38%) Followed by psychosocial interventions Problem: Many different study designs for different approaches made it difficult to compare the outcomes Out of 102 studies 29 are from Europe (28%) - Most studies are from USA and Australia Harm-reduction Evidence for effectiveness of harm-reduction is in general rather scarce Studies focus on relation between service utilisation and the reduction of blood-borne infections and risk behaviour 16.10.2012 10